Delfina F Hlashwayo1,2, Betuel Sigaúque3, Emília V Noormahomed4,5,6, Sónia M S Afonso2, Inácio M Mandomando3,7, Custódio G Bila2. 1. Department of Biological Sciences, Faculty of Sciences, Eduardo Mondlane University, Maputo, Mozambique. 2. Faculty of Veterinary Science, Eduardo Mondlane University, Maputo, Mozambique. 3. Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique. 4. Department of Microbiology, Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique. 5. Infectious Disease Division, Department of Medicine, University of California, San Diego, San Diego, CA, United States of America. 6. Mozambique Institute for Health Education and Research (MIHER), Maputo, Mozambique. 7. Instituto Nacional de Saúde (INS), Ministério da Saúde, Marracuene, Mozambique.
Abstract
INTRODUCTION: Campylobacter spp. are zoonotic bacteria that cause gastroenteritis in humans worldwide, whose main symptom is diarrhea. In certain cases, extra intestinal manifestations may occur, such as Guillain Barré syndrome. The bacteria cause severe diarrhea mostly in children and in immunocompromised individuals. This review aims to address the prevalence of Campylobacter spp. in humans in sub-Saharan Africa. It also aims to understand the impact of HIV in the prevalence, as well as to report data on antibiotic resistance and propose research priorities. METHODS: We followed PRISMA guidelines to find studies on the occurrence of Campylobacter spp. in humans in all countries from sub-Saharan Africa. Studies published between 2000 and 2020 were searched in PubMed, Cochrane Library, CINAHL, African Index Medicus, African Journals Online, Google Scholar and Science Direct. We have conducted a random-effect meta-analysis and calculated the proportion of resistant isolates to different antibiotics. RESULTS AND DISCUSSION: We found 77 studies that described such occurrence in humans in 20 out of 53 sub-Saharan African countries. Campylobacter jejuni was the most prevalent species. Pooled prevalence was 9.9% (CI: 8.4%-11.6%). No major variations within the different sub-regions were found. Most studies reported Campylobacter spp. as the cause of diarrhea, mainly in children. Some studies reported the bacteria as a possible etiologic agent of acute flaccid paralysis and urinary tract infection. Campylobacter spp. presented a higher pooled prevalence in HIV infected patients, although not statistically significant. High proportions of resistant strains were reported for many antibiotics, including erythromycin and tetracycline. CONCLUSION: Campylobacter spp. occur in sub-Saharan Africa, although information is scarce or inexistent for many countries. Research priorities should include investigation of the understudied species; extra intestinal manifestations; the impact of HIV infection and associated risk factors. Control strategies should be reinforced to contain the spread of this pathogen and drug resistance.
INTRODUCTION:Campylobacterspp. are zoonotic bacteria that cause gastroenteritis in humans worldwide, whose main symptom is diarrhea. In certain cases, extra intestinal manifestations may occur, such as Guillain Barré syndrome. The bacteria cause severe diarrhea mostly in children and in immunocompromised individuals. This review aims to address the prevalence of Campylobacterspp. in humans in sub-Saharan Africa. It also aims to understand the impact of HIV in the prevalence, as well as to report data on antibiotic resistance and propose research priorities. METHODS: We followed PRISMA guidelines to find studies on the occurrence of Campylobacterspp. in humans in all countries from sub-Saharan Africa. Studies published between 2000 and 2020 were searched in PubMed, Cochrane Library, CINAHL, African Index Medicus, African Journals Online, Google Scholar and Science Direct. We have conducted a random-effect meta-analysis and calculated the proportion of resistant isolates to different antibiotics. RESULTS AND DISCUSSION: We found 77 studies that described such occurrence in humans in 20 out of 53 sub-Saharan African countries. Campylobacter jejuni was the most prevalent species. Pooled prevalence was 9.9% (CI: 8.4%-11.6%). No major variations within the different sub-regions were found. Most studies reported Campylobacterspp. as the cause of diarrhea, mainly in children. Some studies reported the bacteria as a possible etiologic agent of acute flaccid paralysis and urinary tract infection. Campylobacterspp. presented a higher pooled prevalence in HIV infectedpatients, although not statistically significant. High proportions of resistant strains were reported for many antibiotics, including erythromycin and tetracycline. CONCLUSION:Campylobacterspp. occur in sub-Saharan Africa, although information is scarce or inexistent for many countries. Research priorities should include investigation of the understudied species; extra intestinal manifestations; the impact of HIV infection and associated risk factors. Control strategies should be reinforced to contain the spread of this pathogen and drug resistance.
Authors: Muhammad Nisar; Mansur Ud Din Ahmad; Muhammad Hassan Mushtaq; Wasim Shehzad; Abid Hussain; Mohammad Nasar; Kakambi V Nagaraja; Sagar M Goyal Journal: Acta Trop Date: 2018-04-27 Impact factor: 3.112
Authors: Rebecca M Zash; Roger L Shapiro; Jean Leidner; Carolyn Wester; Alexander J McAdam; Richard L Hodinka; Ibou Thior; Claire Moffat; Joseph Makhema; Kenneth McIntosh; Max Essex; Shahin Lockman Journal: Paediatr Int Child Health Date: 2016-08 Impact factor: 1.990
Authors: I R Lake; F J Colón-González; J Takkinen; M Rossi; B Sudre; J Gomes Dias; L Tavoschi; A Joshi; J C Semenza; G Nichols Journal: Euro Surveill Date: 2019-03
Authors: Noel Gahamanyi; Dae-Geun Song; Kye-Yoon Yoon; Leonard E G Mboera; Mecky I Matee; Dieudonné Mutangana; Erick V G Komba; Cheol-Ho Pan; Raghavendra G Amachawadi Journal: Genes (Basel) Date: 2021-07-25 Impact factor: 4.096
Authors: Said Abukhattab; Haneen Taweel; Arein Awad; Lisa Crump; Pascale Vonaesch; Jakob Zinsstag; Jan Hattendorf; Niveen M E Abu-Rmeileh Journal: Antibiotics (Basel) Date: 2022-04-19
Authors: Alvin Pumelele Ndondo; Brian Eley; Jo Madeleine Wilmshurst; Angelina Kakooza-Mwesige; Maria Pia Giannoccaro; Hugh J Willison; Pedro M Rodríguez Cruz; Jeannine M Heckmann; Kathleen Bateman; Angela Vincent Journal: Front Immunol Date: 2022-03-09 Impact factor: 7.561